Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Financial Performance of Jasper Therapeutics for the Year Ending December 31 2023

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Jasper Therapeutics recorded a net loss of $16.6 million and $64.5 million for the three months and the year ended on December 31, 2023, respectively. The basic and diluted net loss per share for common stockholders were $1.50 and $6.18 during the same periods. The company’s cash and cash equivalents totaled $86.9 million as of December 31, 2023. Research and development expenses for the year ended December 31, 2023, amounted to $51.8 million, with stock-based compensation expenses of $1.6 million included. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

—

On March 4, 2024, Jasper Therapeutics reported a net loss of $16.6 million and $64.5 million for the three months and the year ending on December 31, 2023. The basic and diluted net loss per share attributable to common stockholders were $1.50 and $6.18 for the same periods. Moreover, the company’s cash and cash equivalents as of December 31, 2023, were reported at $86.9 million. Research and development expenses for the year ending December 31, 2023, were $51.8 million, which included stock-based compensation expenses of $1.6 million. General and administrative expenses for the same period were $17.1 million, with stock-based compensation expenses of $3.6 million.

[bs_slider_forecast ticker=”JSPR”]

JSPR Stock Shows Strong Performance with Positive Price Momentum in Pre-Market Trading

On March 4, 2024, JSPR stock had a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock. The price of JSPR shares had increased by $0.83 since the market last closed, representing a 3.91% rise. In pre-market trading on March 4, the stock had risen by an additional $0.67. This strong performance suggests that investors have confidence in JSPR and are optimistic about its future prospects. It is important for investors to continue monitoring JSPR stock and staying informed about any news or developments that may impact its performance.

Currently Playing

JSPR Stock Performance Review: Mixed Data Leaves Investors Uncertain on March 4, 2024

On March 4, 2024, investors in JSPR stock may have been feeling uncertain about the company’s financial performance based on the available data. According to CNN Money, JSPR’s total revenue information was currently unavailable, leaving investors without a key indicator of the company’s financial health.

The data that was available showed that JSPR had experienced a decrease in net income over the past year. The company reported a net income of -$37.69 million for the past year, which was a 23.0% decrease from the previous year. In the most recent quarter, JSPR reported a net income of -$17.54 million, representing a 9.1% decrease from the previous quarter.

Despite the decrease in net income, there was a glimmer of hope for investors in the form of earnings per share (EPS) data. JSPR reported an EPS of -$10.33 for the past year, which actually represented a 61.59% increase from the previous year. However, in the most recent quarter, the company reported an EPS of -$1.60, which was an 8.61% decrease from the previous quarter.

Overall, the mixed performance data for JSPR on March 4, 2024, may have left investors feeling uncertain about the company’s future prospects. While the increase in EPS over the past year was a positive sign, the decreases in net income over the same period could be cause for concern. Without more information on the company’s total revenue, investors may have been left wondering about JSPR’s overall financial health and future performance.

[stock_market_chart symbol=”JSPR” range=”3mo” interval=”1d” settings='{“primaryChartType”:”smoothedLine”,”secondaryChartType”:”column”,”width”:”100%”,”height”:”500px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:14,”color”:”#383838″,”primaryLineColor”:”#5679ff”,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#5679ff”,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#020202″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#e8e8e8″,”scrollbarSelectedBackgroundColor”:”#f7f7f7″,”scrollbarGraphFillColor”:”#435dc2″,”scrollbarSelectedGraphFillColor”:”#92a8fc”,”primaryLineThickness”:2,”secondaryLineThickness”:1,”gridThickness”:1,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”searchMode”:”search”,”mouseWheelZoomEnabled”:false,”cursorEnabled”:true,”exportEnabled”:true,”scrollbarEnabled”:true,”legendEnabled”:true,”periods”:”1D,1M,YTD,ALL”,”defaultPeriod”:”1M”}’]

Tags: JSPR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ projections

Financial Analysts Bullish on Li Auto Stock

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Lyfts Stock Rises After Upgrade from RBC Capital

Pharmaceutical Markets and money

Analyst Raghuram Selvaraju Reiterates Buy Rating for BridgeBio Pharma with 47 Price Target

Recommended

MDB stock news

Insider Trading Activity and Institutional Investment in MongoDB, Inc.: Key Developments to Monitor for Shareholders

3 years ago
Paramount Global Stock

Paramount Global Initiates Major Workforce Reduction Following Merger

3 months ago
Coinbase Stock

Coinbase Bets on Prediction Markets Amid Crypto Uncertainty

3 months ago
Nvidia Stock

Nvidia’s Strategic Gambits Fuel Market Speculation

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Trending

Guaranty Bancshares Stock
Analysis

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

by Jackson Burston
February 7, 2026
0

A strategic acquisition in Texas is proving to be a significant catalyst for Guaranty Bancshares. The bank's...

Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy
  • ServiceNow Shares Face Market Skepticism Despite Record Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com